SCHEMBL25956895

SCHEMBL25956895

COC(=O)C(=O)Nc1cnc(OC)c(C(N)=O)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NNMT P40261 1/20 0.40
▸ ITK Q08881 2/20 0.37
▸ CSF1R P07333 3/20 0.36
▸ PDE4B Q07343 2/20 0.36
▸ GSK3B P49841 1/20 0.36
▸ NPC1 O15118 2/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ EGFR P00533 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ SYK P43405 2/20 0.36
▸ MAPK8 P45983 1/20 0.36
▸ MAPK9 P45984 1/20 0.36
▸ ROCK2 O75116 1/20 0.35
▸ ROCK1 Q13464 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24363780 0.89 NNMT (0.40) NNMTITKCSF1RPDE4BGSK3B
SCHEMBL30469631 0.89 NNMT (0.40) NNMTITKCSF1RPDE4BGSK3B
SCHEMBL29326313 0.89 NNMT (0.40) NNMTITKCSF1RPDE4BGSK3B
SCHEMBL24363776 0.84 MAPK10 (0.35) NNMTCSF1RGSK3BALDH1A1MAPT
SCHEMBL30469699 0.84 MAPK10 (0.35) NNMTCSF1RGSK3BALDH1A1MAPT
SCHEMBL29347659 0.77 NPC1 (0.38) NPC1RAB9AKDM4EALDH1A1LMNA
SCHEMBL26225781 0.75 JAK2 (0.44) NNMTSYK
SCHEMBL24363781 0.73 NNMT (0.47) NNMTGSK3BKDM4EALDH1A1MAPT
SCHEMBL31327199 0.73 NNMT (0.50) NNMTKDM4ESMN1; SMN2ROCK2ROCK1
SCHEMBL26208031 0.73 KMT2A (0.39) NPC1RAB9AKDM4ELMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 — — US disclosed
WO-2023146989-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228478-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 NNMT 1524/4885ITK 4118/4885CSF1R 2230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback